---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000019"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:07:14.740912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M

## Summary
- Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.
- FY 2024 total revenue $1.04B (flat YoY); net loss $190.6M vs. $760.5M loss; adjusted EBITDA $183.1M vs. ($22.3M) loss.
- FY 2025 guidance: revenue $750-850M; adjusted EBITDA $150-200M; segment adjusted gross margin 48-51%.
- NARCAN sales fell 41% in Q4; Smallpox MCM sales surged 565% on ACAM2000 exports; Anthrax MCM down 71%.
- Appointed CEO Joseph Papa; received ~$550M medical countermeasure awards; FDA approved ACAM2000 for mpox prevention.

## SEC filing metadata
- accession: 0001367644-25-000019
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/0001367644-25-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000019
- JSON: https://secwatch.observer/filing/0001367644-25-000019.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.